Inspire Medical Systems, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Inspire Upper Airway Stimulation (UAS) therapy for use in a subset of patients with moderate to severe Obstructive Sleep Apnea (OSA) who are unable to use Continuous Positive Airway Pressure (CPAP). Inspire therapy is a fully implanted neurostimulation device, the first of its kind for sleep apnea, that provides an alternative treatment that is proven, convenient and easy to use.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7169651-fda-approves-inspire-upper-airway-stimulation-therapy-sleep-apnea
Philips Respironics, a unit of Royal Philips Electronics (NYSE: PHG, AEX: PHI) and a pioneer in science-based sleep solutions, is simplifying the design, fitting and care of full-face masks for sleep apnea patients. With its unique modular design, the new Amara full-face mask further demonstrates Philips’ commitment to developing solutions aimed at improving care and outcomes.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57117-philips-respironics-revolutionary-full-face-mask-sleep-therapy
Philips Respironics, a unit of Royal Philips (NYSE: PHG, AEX: PHI) and a pioneer in science-based sleep solutions, today announces a significant advancement in sleep therapy with the commercial release of a first of its kind minimal contact nasal mask – Wisp. Designed to fit more than 98% of sleep apnea patients, Wisp brings distinctive styling and patented technology for a better overall mask experience that may improve patient compliance.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62230-philips-respironics-announces-advancement-in-sleep-therapy-with-wisp
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the Light Study, a long-term research study of Contrave® (naltrexone SR/bupropion SR), a new, investigational drug being evaluated for weight loss, has begun enrolling patients at clinical sites throughout the United States. The Light Study is designed to assess the cardiovascular health outcomes of Contrave.
Nearly 93 million Americans are affected by obesity, and that number is predicted to increase to 120 million Americans within the next five years. More than one-third of adults in the United States are affected by obesity. Obesity increases the risk of heart disease, type 2 diabetes, some types of cancer, sleep apnea, and a variety of other conditions. Medical research suggests that losing just five percent of your body weight can significantly improve your health and reduce the risk of complications from type 2 diabetes and heart disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56480-lightstudy
Philips Respironics, a unit of Royal Philips (NYSE: PHG, AEX: PHIA) and a pioneer in science-based sleep solutions, brings a new comfort option to its best-selling, most comfortable full face mask that fits most patients. The Amara gel cushion option is part of a groundbreaking series of new masks and services that are setting a new standard for patient care.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64501-philips-respironics-amara-gel-cushion-face-mask-sleep-apnea
A call informs Sarah Nealle her six-year-old daughter was in a school bus accident.
Her journey includes: Doctors. An epidural hematoma. Respirators. Apnea tests. Nationwide publicity. Political, moral, ethical, legal, social battles regarding organ transplantation. A family with disagreements.
The lonely decision: how to let her daughter die with dignity. Find out more at http://garybshelly.com/ Literary
